Beyond THC: The New Generation of Cannabinoid Designer Drugs (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/arti...7/?tool=pubmed
The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice' (abst – 2011)http://www.ncbi.nlm.nih.gov/pubmed/21482092
The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography - mass spectrometry (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22522907
Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings (abst – 2012)http://onlinelibrary.wiley.com/doi/1...078.x/abstract
Synthetic Cannabinoids -The Challenges of Testing for Designer Drugs (article – 2013) (funky link- delete the “sign inâ€, and it comes up)http://www.aacc.org/publications/cln...rsonID=206339#
Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1 (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23494106
A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23890687
Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24418231
Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals (full – 2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965957/
Cannabinoids as therapeutic agents in cancer: current status and future implications (link to PDF- 2014)http://www.impactjournals.com/oncota...e&op=view&path[]=2233
The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice' (abst – 2011)http://www.ncbi.nlm.nih.gov/pubmed/21482092
The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography - mass spectrometry (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22522907
Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings (abst – 2012)http://onlinelibrary.wiley.com/doi/1...078.x/abstract
Synthetic Cannabinoids -The Challenges of Testing for Designer Drugs (article – 2013) (funky link- delete the “sign inâ€, and it comes up)http://www.aacc.org/publications/cln...rsonID=206339#
Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1 (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23494106
A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23890687
Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24418231
Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals (full – 2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965957/
Cannabinoids as therapeutic agents in cancer: current status and future implications (link to PDF- 2014)http://www.impactjournals.com/oncota...e&op=view&path[]=2233